KPT-276 is primarily investigated for its potential in cancer therapy, particularly in targeting and inhibiting the export of tumor suppressor proteins from the nucleus. By blocking the nuclear export machinery, it helps retain these proteins within the nucleus, promoting their anti-cancer activity. This mechanism makes it a promising candidate for treating various cancers, including those resistant to conventional therapies. Research is ongoing to explore its efficacy in preclinical models and its potential use in combination with other anticancer agents to enhance treatment outcomes.